About Allscripts Healthcare Solutions (NASDAQ:MDRX)
Allscripts Healthcare Solutions, Inc. (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions. The Population Health segment includes the sale of health management and coordinated care solutions, which focus on hospitals, health systems, other care facilities and accountable care organizations (ACOs). The Netsmart segment provides software and technology solutions to the health and human services industry, which includes behavioral health, addiction treatment, intellectual and developmental disability services, child and family services and public health segments, as well as to post-acute home care organizations.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Software & Technology Services
- Sub-Industry: Health Care Technology
- Symbol: NASDAQ:MDRX
- CUSIP: 01988P10
- Web: www.allscripts.com
- Market Cap: $2.54302 billion
- Outstanding Shares: 180,612,000
- 50 Day Moving Avg: $13.83
- 200 Day Moving Avg: $12.71
- 52 Week Range: $9.80 - $14.45
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 24.70
- P/E Growth: 1.27
- Annual Revenue: $1.66 billion
- Price / Sales: 1.53
- Book Value: $6.23 per share
- Price / Book: 2.26
- EBITDA: $160.09 million
- Net Margins: -11.54%
- Return on Equity: 5.97%
- Return on Assets: 1.96%
- Debt-to-Equity Ratio: 1.13%
- Current Ratio: 0.93%
- Quick Ratio: 0.93%
- Average Volume: 2.40 million shs.
- Beta: 1.31
- Short Ratio: 9.63
Frequently Asked Questions for Allscripts Healthcare Solutions (NASDAQ:MDRX)
What is Allscripts Healthcare Solutions' stock symbol?
Allscripts Healthcare Solutions trades on the NASDAQ under the ticker symbol "MDRX."
How were Allscripts Healthcare Solutions' earnings last quarter?
Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) issued its quarterly earnings data on Thursday, August, 3rd. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by $0.04. The company had revenue of $426.10 million for the quarter, compared to analysts' expectations of $424.94 million. Allscripts Healthcare Solutions had a negative net margin of 11.54% and a positive return on equity of 5.97%. The company's revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the company earned $0.14 earnings per share. View Allscripts Healthcare Solutions' Earnings History.
When will Allscripts Healthcare Solutions make its next earnings announcement?
What guidance has Allscripts Healthcare Solutions issued on next quarter's earnings?
Allscripts Healthcare Solutions updated its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $0.61-0.63 for the period, compared to the Thomson Reuters consensus estimate of $0.62.
Where is Allscripts Healthcare Solutions' stock going? Where will Allscripts Healthcare Solutions' stock price be in 2017?
19 brokerages have issued 1-year price targets for Allscripts Healthcare Solutions' stock. Their predictions range from $12.00 to $19.00. On average, they anticipate Allscripts Healthcare Solutions' share price to reach $15.24 in the next year. View Analyst Ratings for Allscripts Healthcare Solutions.
What are analysts saying about Allscripts Healthcare Solutions stock?
Here are some recent quotes from research analysts about Allscripts Healthcare Solutions stock:
- 1. According to Zacks Investment Research, "Over the last year, Allscripts has traded below the broader industry in terms of price. Allscripts exited the second quarter on a favorable note, wherein adjusted earnings were in line with the Zacks Consensus Estimate, while revenues beat the same. A solid guidance for full-year 2017 and a strong long-term outlook are the key highlights at the moment. Allscripts announced its plans to takeover the hospital and health system business from McKesson Corporation, which is expected to close by the fourth quarter. Allscripts’ continued reliance on mergers and acquisition activities presents a substantial integration risk for the company. Furthermore, intensifying market competition is a major dampener for Allscripts. The company also expects a modest increase in operating expenses during the second half of the year to support business growth." (10/10/2017)
- 2. Cantor Fitzgerald analysts commented, "2Q17 recap. Non-GAAP revenue was $428 million compared to FactSet consensus of $426 million. With Netsmart now mostly annualized, non-GAAP revenue grew 7.8% y/y. Adjusted EPS was $0.15 (in line with our estimate and consensus) vs. $0.14 a year ago. Bookings were impressive and grew to $407 million." (8/14/2017)
- 3. Maxim Group analysts commented, "1Q17 bookings of $286M, up 13.5% y/y, were below our estimate of $302M and consensus of $298M." (5/5/2017)
- 4. Citigroup Inc. analysts commented, "We are upgrading MDRX shares to Buy following its recent analyst day. Allscripts provided targets for 2018 - 2020 revenue growth of 6%-8% and EPS growth of 12%-15%, both of which are ahead of our forecasts but approximately in-line with the Street. Allscripts is beginning to show better results as non-recurring revenue has stabilized, recurring revenue grows faster, and the mix continues to shift to recurring revenue, with non EMR solutions seeing faster growth. We believe that if Allscripts can hit these targets investors could see a 20% return on the shares this year from current levels." (3/24/2017)
- 5. Piper Jaffray Companies analysts commented, "We attended Allscripts' Investor Conference yesterday where management discussed its plan to deliver its FY17 guidance and long term growth targets. We believe 6-8% revenue growth and 12-15% EPS growth are achievable, provided the non-recurring revenue has surpassed its decline, and the Platform as a Service model continues to grow. We are tapering our FY18 EPS estimate to be in line with targets while maintaining our 20x EPS valuation, which brings our PT to $14 from $15. Reiterate Neutral." (3/22/2017)
Are investors shorting Allscripts Healthcare Solutions?
Allscripts Healthcare Solutions saw a drop in short interest in the month of September. As of September 15th, there was short interest totalling 20,145,704 shares, a drop of 16.7% from the August 31st total of 24,175,514 shares. Based on an average daily trading volume, of 2,996,129 shares, the days-to-cover ratio is presently 6.7 days. Currently, 11.4% of the shares of the company are short sold.
Who are some of Allscripts Healthcare Solutions' key competitors?
Some companies that are related to Allscripts Healthcare Solutions include athenahealth (ATHN), Cotiviti Holdings (COTV), HealthEquity (HQY), Omnicell (OMCL), Evolent Health (EVH), Emis Group Plc (EMIS), Castlight Health, inc. (CSLT), Tabula Rasa Healthcare (TRHC), NantHealth (NH), Craneware plc (CRW), Simulations Plus (SLP), Fluidigm Corporation (FLDM), Medical Transcription Billing, Corp. (MTBC), Constellation Healthcare Tech (CHT) and Press Ganey Holdings (PGND).
Who are Allscripts Healthcare Solutions' key executives?
Allscripts Healthcare Solutions' management team includes the folowing people:
- Michael A. Klayko, Independent Chairman of the Board
- Richard J. Poulton, President
- Paul M. Black, Chief Executive Officer, Director
- Dennis M. Olis, Interim Chief Financial Officer, Principal Accounting Officer
- James R. Hewitt, Executive Vice President, Solutions Development
- Lisa Khorey, Executive Vice President, Chief Client Delivery Officer
- Brian P. Farley, Senior Vice President, General Counsel and Corporate Secretary;
- Mara Glickman Aspinall, Independent Director
- P. Gregory Garrison, Independent Director
- Jonathan J. Judge, Independent Director
Who owns Allscripts Healthcare Solutions stock?
Allscripts Healthcare Solutions' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (1.30%), Mutual of America Capital Management LLC (0.08%), Tributary Capital Management LLC (0.07%) and State Treasurer State of Michigan (0.04%). Company insiders that own Allscripts Healthcare Solutions stock include Brian Farley, Dennis Olis, James Hewitt, Paul Black and Richard J Poulton. View Institutional Ownership Trends for Allscripts Healthcare Solutions.
Who sold Allscripts Healthcare Solutions stock? Who is selling Allscripts Healthcare Solutions stock?
Allscripts Healthcare Solutions' stock was sold by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan and Mutual of America Capital Management LLC. Company insiders that have sold Allscripts Healthcare Solutions stock in the last year include Brian Farley, Paul Black and Richard J Poulton. View Insider Buying and Selling for Allscripts Healthcare Solutions.
Who bought Allscripts Healthcare Solutions stock? Who is buying Allscripts Healthcare Solutions stock?
How do I buy Allscripts Healthcare Solutions stock?
Shares of Allscripts Healthcare Solutions can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allscripts Healthcare Solutions' stock price today?
MarketBeat Community Rating for Allscripts Healthcare Solutions (NASDAQ MDRX)MarketBeat's community ratings are surveys of what our community members think about Allscripts Healthcare Solutions and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Allscripts Healthcare Solutions stock can currently be purchased for approximately $14.08.
Consensus Ratings for Allscripts Healthcare Solutions (NASDAQ:MDRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 6 Hold Ratings, 12 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.58)|
|Consensus Price Target: ||$15.24 (8.21% upside)|Consensus Price Target History for Allscripts Healthcare Solutions (NASDAQ:MDRX)
Analysts' Ratings History for Allscripts Healthcare Solutions (NASDAQ:MDRX)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/17/2017||Robert W. Baird||Reiterated Rating||Buy||$16.00||N/A|
|10/3/2017||Dougherty & Co||Reiterated Rating||Buy||$15.00 -> $16.00||Low|
|9/27/2017||Cantor Fitzgerald||Reiterated Rating||Buy||$17.00||Low|
|9/19/2017||Royal Bank Of Canada||Initiated Coverage||Outperform -> Outperform||$17.00||Medium|
|9/11/2017||Cowen and Company||Upgrade||Market Perform -> Outperform||$13.00 -> $16.00||High|
|8/25/2017||Jefferies Group LLC||Set Price Target||Buy||$17.00||Low|
|8/7/2017||Citigroup Inc.||Boost Price Target||Neutral||$13.00 -> $14.00||Low|
|8/7/2017||Morgan Stanley||Boost Price Target||Underweight||$11.00 -> $12.00||Low|
|8/4/2017||Maxim Group||Reiterated Rating||Buy||$16.00||High|
|7/21/2017||Piper Jaffray Companies||Reiterated Rating||Hold||$14.00||Low|
|6/19/2017||Leerink Swann||Downgrade||Outperform -> Market Perform||$15.00 -> $13.00||Medium|
|5/15/2017||Bank of America Corporation||Initiated Coverage||Neutral||$14.00||High|
|3/27/2017||Wells Fargo & Company||Upgrade||Market Perform -> Outperform||High|
|3/24/2017||Deutsche Bank AG||Upgrade||Hold -> Buy||$12.50 -> $14.00||Low|
|2/17/2017||Oppenheimer Holdings, Inc.||Reiterated Rating||Hold||N/A|
|1/8/2017||FBR & Co||Reiterated Rating||Hold||$12.00||N/A|
|1/3/2017||Canaccord Genuity||Reiterated Rating||Buy||$17.00||N/A|
|10/30/2016||J P Morgan Chase & Co||Initiated Coverage||Buy||$15.00||N/A|
|8/5/2016||Goldman Sachs Group, Inc. (The)||Boost Price Target||Neutral||$14.00 -> $16.00||N/A|
|2/24/2016||SunTrust Banks, Inc.||Lower Price Target||Buy||$18.00 -> $15.00||N/A|
|2/19/2016||Barclays PLC||Lower Price Target||Equal Weight||$15.00 -> $14.00||N/A|
|1/5/2016||Topeka Capital Markets||Boost Price Target||Hold||$14.00 -> $15.00||N/A|
|1/4/2016||Raymond James Financial, Inc.||Downgrade||Outperform -> Market Perform||N/A|
|11/6/2015||Evercore ISI||Boost Price Target||Hold||$14.00 -> $15.00||N/A|
Earnings History for Allscripts Healthcare Solutions (NASDAQ:MDRX)Earnings History by Quarter for Allscripts Healthcare Solutions (NASDAQ MDRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/3/2017||Q2 2017||$0.15||$0.11||$424.94 million||$426.10 million||View||Listen|
|5/4/2017||Q1 2017||$0.09||$0.10||$415.20 million||$415.00 million||View||Listen|
|2/16/2017||Q4 2016||$0.15||$0.14||$424.11 million||$425.40 million||View||Listen|
|11/3/2016||Q3||$0.15||$0.14||$414.92 million||$392.40 million||View||Listen|
|8/4/2016||Q2||$0.14||$0.14||$403.13 million||$386.50 million||View||Listen|
|5/5/2016||Q1||$0.12||$0.13||$348.51 million||$346.00 million||View||Listen|
|2/18/2016||Q4||$0.13||$0.13||$357.91 million||$345.60 million||View||Listen|
|11/5/2015||Q315||$0.12||$0.13||$354.67 million||$355.00 million||View||Listen|
|8/4/2015||Q215||$0.11||$0.12||$347.13 million||$351.70 million||View||Listen|
|5/7/2015||Q115||$0.09||$0.08||$344.73 million||$335.00 million||View||Listen|
|2/26/2015||Q414||$0.09||$0.09||$358.10 million||$343.00 million||View||Listen|
|11/6/2014||Q314||$0.10||$0.06||$353.00 million||$348.00 million||View||Listen|
|8/7/2014||Q214||$0.09||$0.09||$353.12 million||$351.30 million||View||Listen|
|5/8/2014||Q114||$0.07||$0.07||$347.98 billion||$340.30 billion||View||Listen|
|2/20/2014||Q413||$0.08||$0.08||$343.47 million||$351.00 million||View||Listen|
|11/7/2013||Q313||$0.08||$0.05||$355.30 million||$334.00 million||View||Listen|
|8/8/2013||Q2 2013||$0.11||$0.09||$360.00 million||$344.80 million||View||Listen|
|5/9/2013||Q1 2013||$0.14||$0.09||$368.11 million||$347.10 million||View||Listen|
|2/19/2013||Q4 2012||$0.21||$0.16||$367.07 million||$367.70 million||View||Listen|
|11/8/2012||Q312||$0.22||$0.23||$376.97 million||$361.00 million||View||N/A|
Earnings Estimates for Allscripts Healthcare Solutions (NASDAQ:MDRX)
2017 EPS Consensus Estimate: $0.47
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Allscripts Healthcare Solutions (NASDAQ:MDRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Allscripts Healthcare Solutions (NASDAQ:MDRX)
Insider Ownership Percentage: 0.75%Insider Trades by Quarter for Allscripts Healthcare Solutions (NASDAQ:MDRX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/15/2017||Richard J. Poulton||President||Sell||15,000||$13.56||$203,400.00|| |
|9/14/2017||Brian Farley||EVP||Sell||5,000||$13.52||$67,600.00|| |
|9/14/2017||Paul Black||CEO||Sell||15,000||$13.52||$202,800.00|| |
|5/16/2017||Richard J Poulton||President||Sell||25,000||$12.06||$301,500.00|| |
|3/23/2017||Brian Farley||SVP||Sell||15,000||$11.63||$174,450.00|| |
|9/15/2016||James Hewitt||SVP||Sell||17,500||$13.00||$227,500.00|| |
|9/15/2016||Paul Black||CEO||Sell||15,000||$13.00||$195,000.00|| |
|7/11/2016||Dennis Olis||SVP||Sell||7,000||$14.00||$98,000.00|| |
|7/1/2016||James Hewitt||SVP||Sell||17,500||$13.00||$227,500.00|| |
|6/13/2016||Paul Black||CEO||Sell||15,000||$13.04||$195,600.00|| |
|6/13/2016||Richard J Poulton||President||Sell||10,000||$13.03||$130,300.00|| |
|4/7/2016||Dennis Olis||SVP||Sell||25,000||$14.00||$350,000.00|| |
|3/30/2016||James Hewitt||SVP||Sell||17,500||$13.31||$232,925.00|| |
|3/30/2016||Paul Black||CEO||Sell||15,000||$13.31||$199,650.00|| |
|3/14/2016||Richard J Poulton||President||Sell||5,000||$12.85||$64,250.00|| |
|8/17/2015||James Hewitt||SVP||Sell||70,000||$14.17||$991,900.00|| |
|12/12/2014||Paul Black||CEO||Buy||6,500||$11.51||$74,815.00|| |
|11/18/2014||Anita Pramoda||Director||Buy||2,017||$12.25||$24,708.25|| |
|11/13/2014||Dennis Chookaszian||Director||Buy||10,000||$12.43||$124,300.00|| |
|11/11/2014||Dennis Olis||SVP||Buy||4,400||$11.26||$49,544.00|| |
|11/11/2014||Paul Black||CEO||Buy||22,180||$11.26||$249,746.80|| |
|11/11/2014||Richard J Poulton||CFO||Buy||4,500||$11.26||$50,670.00|| |
|11/11/2014||Stuart L Bascomb||Director||Buy||6,743||$11.26||$75,926.18|| |
|8/18/2014||Michael Klayko||Director||Buy||3,500||$14.41||$50,435.00|| |
|3/13/2014||Deborah Snow||SVP||Sell||14,740||$18.75||$276,375.00|| |
|11/21/2013||Deborah Snow||SVP||Sell||2,400||$14.70||$35,280.00|| |
|9/9/2013||Clifford B Meltzer||EVP||Sell||35,000||$14.56||$509,600.00|| |
|8/15/2013||Michael Klayko||Director||Buy||10,000||$14.80||$148,000.00|| |
|5/30/2013||Deborah Snow||SVP||Sell||1,495||$13.71||$20,496.45|| |
|5/20/2013||Stuart L Bascomb||Director||Buy||3,701||$14.02||$51,888.02|| |
|5/15/2013||Paul Black||CEO||Buy||7,120||$14.02||$99,822.40|| |
|5/14/2013||Steve Shute||VP||Sell||14,612||$14.10||$206,029.20|| |
|3/12/2013||Paul Black||CEO||Buy||23,625||$12.69||$299,801.25|| |
|3/12/2013||Stuart L Bascomb||Director||Buy||10,000||$12.64||$126,400.00|| |
Headline Trends for Allscripts Healthcare Solutions (NASDAQ:MDRX)
Latest Headlines for Allscripts Healthcare Solutions (NASDAQ:MDRX)
Loading headlines, please wait.
Allscripts Healthcare Solutions (MDRX) Chart for Sunday, October, 22, 2017